Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins--theoretical and practical aspects.

T Hofstaetter, P Gronski, F R Seiler

    Behring Institute Mitteilungen
    |May 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    IgG dimers in multidonor-derived immunoglobulins: aspects of generation and function.

    Current pharmaceutical design·2006
    Same author

    Indications of neutralising anti-idiotypic antibodies and selective proteolytic fragmentation in polyclonal anti-D IgG preparations.

    Biologicals : journal of the International Association of Biological Standardization·2003
    Same author

    Biology of natural and recombinant soluble interleukin-4 receptor.

    Behring Institute Mitteilungen·1995
    Same author

    Monomeric and dimeric forms of soluble receptors can differ in their neutralization potential.

    Behring Institute Mitteilungen·1995
    Same author

    Regulation of IL-1 activity by soluble IL-1 receptors.

    Behring Institute Mitteilungen·1995
    Same author

    Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats.

    Transplantation proceedings·1995
    Same journal

    Clinical Experience with ALG.

    Behring Institute Mitteilungen·2010
    Same journal

    Production of a Standardized Anti-Lymphocyte Globulin.

    Behring Institute Mitteilungen·2010
    Same journal

    Immunosuppression and Neoplasia.

    Behring Institute Mitteilungen·2010
    Same journal

    Molecular and Immunological Aspects of Host-Parasite Interactions. Symposium proceedings. Wurzburg, Germany, June 6-8, 1996.

    Behring Institute Mitteilungen·1997
    Same journal

    The galactose-inhibitable surface lectin of Entamoeba histolytica, a possible candidate for a subunit vaccine to prevent amoebiasis.

    Behring Institute Mitteilungen·1997
    Same journal

    Plasmodium vivax: epitope mapping of monoclonal antibodies against the N-terminal region of the merozoite surface protein 1.

    Behring Institute Mitteilungen·1997
    See all related articles

    Clinical use of immunotoxins faces challenges with antibody-drug components and conjugate formation. This review explores these issues and proposes solutions for improved immunotoxin therapy.

    Area of Science:

    • Immunotherapy
    • Bioconjugation Chemistry
    • Pharmacology

    Background:

    • Clinical application of immunotoxins is limited by unresolved issues.
    • Difficulties exist with antibody, coupling agent, and cytotoxic drug components.
    • Conjugate formation and immunotoxin pharmacokinetics present significant obstacles.

    Purpose of the Study:

    • To review the challenges hindering immunotoxin clinical application.
    • To identify and discuss problems related to immunotoxin components and formation.
    • To propose potential solutions and model immunotoxins.

    Main Methods:

    • Literature review of immunotoxin challenges.
    • Analysis of problems associated with immunotoxin components (antibody, linker, drug).

    Related Experiment Videos

  • Discussion of conjugate formation and pharmacokinetic data gaps.

    • Main Results:

    • Identified key difficulties in antibody-drug conjugate (ADC) design and production.
    • Highlighted lack of pharmacokinetic and cell-fate data for immunotoxins.
    • Proposed solutions and conceptual models for improved immunotoxin development.

    Conclusions:

    • Overcoming component-specific and formation-related issues is crucial for immunotoxin success.
    • Further research into immunotoxin pharmacokinetics and target cell interactions is needed.
    • The development of novel immunotoxins requires addressing current limitations and exploring innovative strategies.